Can a biological stock be held for a long time?

A word of advice to all retail investors who hold or want to buy Antu shares: At present, Antu's way is most likely to reduce all the rising profits of 19 to around 45 yuan. You can turn out the annual chart and see that you really shouldn't take over the position at this moment, except those who are not afraid of death. It's not the darkest time to boil in warm water every day like a frog. Once it is darkest, it is the opportunity to enter the market after the volume is enlarged!

：

Antu Biology is specialized in the research and development, manufacture, integration and service of in vitro diagnostic reagents and instruments. The detection fields covered by products include immunity, microorganism, biochemistry and so on. At the same time, it has been further developed in the fields of molecular detection, and can also provide comprehensive product solutions and overall services for medical laboratories. Among them, chemiluminescence is actually the largest subdivision in the field of in vitro diagnosis, and Antu Bio belongs to the top companies among domestic chemiluminescence enterprises.

Household in vitro diagnostic chemiluminescence faucet

In 20 13, the series of magnetic powder chemiluminescence products went on the market, and Antu Bio became the first enterprise in China to launch a magnetic powder chemiluminescence technology platform with a single random detection of 200 t/h. At present, Antu Bio has listed three products, and the output of chemiluminescence instruments ranks first in China, which not only meets the detection needs of hospitals of different levels, but also has high recognition from Antu Chemiluminescence Reagent Hospital. The detection results are almost close to the international gold standard, and it has the basis of imported alternative technology.

Endogenous growth+extension mergers and acquisitions, strengthen the leading position.

Its R&D strength, product strength and channel strength have all been verified by Antu biochemical luminescent products, which constitutes the diversified development of immunology, biochemistry, microbiology and molecular diagnosis. The investment in R&D makes R&D personnel and R&D expenses increase year by year, constantly improving R&D innovation strength, developing new products, and escorting the company's long-term development.

At the same time, Antu Bio continues to help itself become bigger and stronger through acquisition. In 20 16-20 17, the acquisition of Shi Sheng Junhui won the general agent right of Antu Bio-Toshiba Biochemical Instrument 10 in China, and the acquisition of Biotek enabled Antu Bio to obtain the biochemical testing project 1 19, further consolidating its leading position.